Table 1 Characteristics of the included studies
From: Effectiveness and safety of stem cell therapy for diabetic foot: a meta-analysis update
Author, year | Country | Study design | Mean age (treatment group, years) | Participant cases (treatment group/control) | Cell type | Amount of cells | Method | Control | Follow-up (month) |
|---|---|---|---|---|---|---|---|---|---|
Huang, 2005 | China | Rct | 71 | 14/14 | PBMNCs | 3*109/leg | i.m | PGE1 | 3 |
Dash, 2009 | India | Rct | 3/3 | BMMSCs | 106/cm2 | i.m | None | 3 | |
Han, 2010 | Korea | Rct | 67 | 26/26 | PLAS | > 4 × 106/ulcer | Ad.us.ext | None | 2 |
Lu, 2011 | China | Rct | 65 | 41/41 | BMMNCs | 9.6*108/ leg | i.m | NS | 6 |
BMMSCs | 9.3*108/leg | i.m | NS | 6 | |||||
Jain, 2011 | India | Rct | 54 | 23/24 | BMDC | 5 ml/leg | Peripheral blood | 3 | |
Kirana, 2012 | Germany | Rct | 69 | 12/6 | BMMNCs | 3*108/leg | i.m. or i.a | None | 11 |
20/6 | BMTRCs | 8*107/leg | i.m. or i.a | None | 11 | ||||
Ozturk, 2012 | Turkey | Rct | 71 | 20/20 | PBMNCs | 2*107/leg | i.m | Conservative treatment | 3 |
Dubsky, 2013 | Czech Republic | Cct | 61 | 17/22 | BMMNCs | 2.2*109/leg | i.m | Conservative treatment | 6 |
63 | 11/22 | PBPCs | 2.4*1010/leg | i.m | Conservative treatment | 6 | |||
Mohammadzadeh, 2013 | Iran | Rct | 64 | 7/14 | PBMSCs | 9–12*108/leg | i.m | Sterile PBS | 3 |
He, 2013 | China | Rct | 63 | 50/50 | HUCMSCs | 5.8–8.2*107/ leg | i.m | Conservative treatment | 3 |
DUBSKÝ | Czech Republic | Retrospective | 63 | 31/23 | BMMNCs + PBPCs | None | i.m | Conservative treatment | 12 |
Qin, 2016 | China | Rct | 75 | 28/25 | HUCMSCs | 4.8–8.6*107/leg | i.m | Conservative treatment | 3 |
Zhang, 2016 | China | Cct | 71 | 27/26 | CD133+ cells | ≥ 1 × 107/leg | i.a | NS | 18 |
Leone, 2019 | Italy | Rct | 69 | 55/55 | MFAT | 10-30 ml/ leg | i.r.w | None | 6 |